Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921287 | 0.92 | P2RY12 (0.63) | P2RY12CNR2MEN1GPR55SLC6A7 | |
| SCHEMBL4921046 | 0.90 | P2RY12 (0.75) | P2RY12MEN1 | |
| SCHEMBL4914969 | 0.86 | P2RY12 (0.65) | P2RY12CNR2MEN1GPR55SLC6A7 | |
| SCHEMBL4915963 | 0.86 | P2RY12 (0.63) | P2RY12CNR2GPR55SLC6A7 | |
| SCHEMBL4918576 | 0.86 | P2RY12 (0.63) | P2RY12CNR2GPR55SLC6A7 | |
| SCHEMBL4897189 | 0.85 | P2RY12 (0.81) | P2RY12CNR2MEN1GPR55SLC6A7 | |
| SCHEMBL4910925 | 0.85 | P2RY12 (0.83) | P2RY12 | |
| SCHEMBL4922072 | 0.83 | P2RY12 (0.53) | P2RY12CNR2MEN1GPR55 | |
| SCHEMBL4885638 | 0.82 | P2RY12 (0.82) | P2RY12CNR2MEN1GPR55SLC6A7 | |
| SCHEMBL4894358 | 0.82 | P2RY12 (0.82) | P2RY12CNR2MEN1GPR55SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | P2RY12 24/4885CNR2 695/4885MEN1 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.